Morningstar

Anavex Life Sciences Gets FDA OK for Clinical Study of Genetic Disorder Treatment

Provided by Dow Jones

By Elias Schisgall 




  Anavex Life Sciences will proceed with a clinical study of a new drug to treat the genetic disorder Fragile X syndrome after getting clearance from U.S. regulators. 



  The company said the Food and Drug Administration cleared the study under an investigational new drug application for Anavex 2-73, known generically as blarcamesine. 



  The drug had previously been named an orphan drug by the FDA. 



  "FDA clearance of the Fragile X IND is an important milestone that gives Anavex open INDs in all three of our core indications: Alzheimer's Disease, Rett syndrome, and Fragile X syndrome, and supports our continued momentum of working closely with the FDA as we move our programs forward," interim Chief Executive Terrie Kellmeyer said. 





  Write to Elias Schisgall at elias.schisgall@wsj.com 





  (END) Dow Jones Newswires



  October 15, 2026 16:49 ET (20:49 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
5 Stocks to Sell for Tax-Loss Harvesting 
 
Plus, earnings season kicks off with big banks. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
33 Undervalued Stocks to Buy Before the Market Shifts Again
 
Here’s the new list of Morningstar’s top analyst picks for the fourth quarter of 2026. 
 
 
Susan Dziubinski and Tori Brovet 
 
 
 
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
 
Even short-term muni funds aren’t totally immune from losses. 
 
 
Amy C. Arnott, CFA 
 
 
 
What’s Ahead for Stocks This Quarter—and Where to Invest
 
Morningstar’s chief market strategist and economist share their outlooks for the fourth quarter of 2026. 
 
 
David Sekera, CFA, Preston Caldwell, and Susan Dziubinski 
 
 
 
Where to Find Durable Dividends in Today’s Stock Market
 
In tough times for equity income, investors must beware of yield traps.  
 
 
Dan Lefkovitz 
 
 
 
 

			Sponsor Center